Amedisys Inc's ROA from the second quarter of 2025 to the second quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Amedisys Inc's ROA in the second quarter of 2025?
Amedisys Inc achieved a return on average assets (ROA) of 3.85 % in its second quarter of 2025, this is above AMED's average return on assets of 3.22%.
Amedisys Incs assets during the 12 months ending in the second quarter of 2025 are valued at $2 billion

ROA decreased relative to the period ending Mar 31 2025, due to the decline in net income.

However, within the Healthcare sector 161 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the first quarter of 2025 from 1372 to 1404.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter	(Dec 31 2024) IV. Quarter	(Sep 30 2024) III. Quarter	(Jun 30 2024) II. Quarter
Y / Y Total Assets Change	8.81 %	9.03 %	4.21 %	5.88 %	7.2 %
Y / Y Net Income Change	-10.81 %	323.61 %	-	-35.53 %	-
Net Income (TTM) in million	82	85	38	83	92
Return On Assets (TTM)	3.85 %	4.1 %	1.87 %	4.1 %	4.61 %
AMED's Total Ranking	# 1404	# 1372	# 2208	# 1427	# 1343
Total Assets (TTM) in million	2,215	2,185	2,058	2,056	2,036
Seq. Total Assets Change	1.41 %	6.14 %	0.09 %	0.99 %	1.62 %
Seq. Net Income Change	-53.01 %	-	-	-49.3 %	123.19 %

AMED's 5 Years Annual ROA >> Back to AMED Management Effectiveness >> Compare AMED ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 21
Sector	# 162
Overall	# 1389

Return On Assets Statistics
High	Average	Low
15.81 %	3.22 %	-30.27 %
(Dec 31 2018)		(Sep 30 2011)

Financial Statements
Amedisys Inc's Assets	$ 2,215 million	AMED's Balance sheet
Amedisys Inc's Income	$ 29 million	Quarterly AMED's Income Statement
AMED's Income by Division		See AMED's Income by Division

Annual Return On Assets	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021	(Dec 31 2020) FY 2020
Y / Y Total Assets Change	4.21 %	5.31 %	6.78 %	22.86 %	13.21 %
Total Assets in million	2,058	1,975	1,876	1,756	1,430
Y / Y Net Income Change	-	-	-44 %	13.49 %	44.78 %
Net Income in million	38	-11	118	210	185
Annual Return On Assets	1.85 %	-0.55 %	6.28 %	11.97 %	12.95 %

AMED's 5 Years Annual ROA >> Back to AMED Management Effectiveness >> Compare AMED ROA to its Competitors

Comment on AMED's ROA in the fiscal year ending 2024

In the fiscal year 2024 ROA improved to 1.85 % compared to prior year, due to annual net income growth of % to $38.16 million, while value of Amedisys Inc's overall assets grew just by 4.21 % to $2,058.23 million, compared to $2,058.23 a year before.

More Return On Assets Ratios
AMED's' Return on Assets at Yahoo Finance
Healthcare Facilities Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
AMED's Roa Ratio versus Healthcare Facilities Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for AMED's Competitors
Subscribers only: Roa for Amedisys Inc's Suppliers
Subscribers only: Return On Assets for AMED's Customers

You may also want to know
AMED's Roi	AMED's Inventory Turnover Ratio	AMED's Growth Rates	AMED's Dividend Comparisons
	AMED's Profitability Ratios	AMED's Asset Turnover Ratio	AMED's Dividend Growth
AMED's Roe	AMED's Valuation Ratios	AMED's Financial Strength Ratios	AMED's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2025, within Healthcare Sector	ROA
Ufp Technologies Inc	10.55 %
Encompass Health Corporation	10.49 %
Eledon Pharmaceuticals Inc	10.36 %
Champions Oncology Inc	10.23 %
Caredx Inc	10.19 %
Agilent Technologies inc	10.15 %
Cryoport inc	10.14 %
Utah Medical Products Inc	10.13 %
3m Company	9.96 %
Emergent Biosolutions Inc	9.77 %
Tg Therapeutics Inc	9.59 %
Black Diamond Therapeutics Inc	9.58 %
Penumbra Inc	9.41 %
Neurocrine Biosciences Inc	9.39 %
Biomarin Pharmaceutical Inc	9.24 %
Lemaitre Vascular Inc	9.14 %
Royalty Pharma Plc	8.90 %
Universal Health Services Inc	8.77 %
Protalix Biotherapeutics inc	8.73 %
Transmedics Group Inc	8.64 %
Dexcom Inc	8.49 %
Amphastar Pharmaceuticals Inc	8.47 %
Tenet Healthcare Corp	8.25 %
Escalon Medical Corp	8.18 %
Viemed Healthcare Inc	8.06 %
Mannkind Corporation	7.81 %
Progyny Inc	7.70 %
Kewaunee Scientific Corporation	7.61 %
Protagonist Therapeutics inc	7.41 %
Amgen Inc	7.35 %

Date modified: 2026-06-22T14:32:45+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.